Targovax ASA: Interim Report second quarter and first half year 2016

Oslo, Norway, 25 August 2016 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its second quarter and first half year 2016 results. A meeting for investors, analysts and press will take place in Oslo...

London, 25/08/2016 (informazione.it - comunicati stampa - salute e benessere)

      
Preparation of new combination clinical trials progressed according to plan. At the moment four new studies are in the process of being set up. In June Targovax recruited and dosed the first patient in the Phase Ib/II trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with chemotherapy. This trial is planned to include six patients in the lead-in for safety evaluation of the combination treatment, and approximately 24 patients in a randomized second part to compare the tumor targeted immune activation of the combination treatment with the standard of care chemotherapy.

In July 2016, Targovax raised NOK 110 million in new equity. The transaction closed on 7 July 2016 and Targovax listed the next day on Oslo Axess under the ticker TRVX.

"Targovax develops according to plan. I am especially pleased that we recruited our first patient in our mesothelioma trial and that we could present positive data for our peptide immune therapy. The recent IPO means that we have funding to start and get data from six new trials", says CEO Gunnar Gårdemyr.

The presentation will take place at 10:00 CET at:

Hotel Continental
Stortingsgaten 24/26
0117 Oslo

The presentation will also be webcast live and can be accessed through www.targovax.com.

At 14:00 CET (08:00 EST) The company will host a telephone conference which will include a presentation of the results, following a Q&A session.  CEO Gunnar Gårdemyr and CFO Øystein Soug will present the company.  Call in details can be found below.

Call-in numbers:
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077

Access code: 72735642#

Please make sure to dial in at least 5-10 minutes ahead to complete your registration.

See attached list for more dial-in numbers.
http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Access_List.pdf

The quarterly report and presentation are also available at the website  www.targovax.com.

Gunnar Gårdemyr, CEO
Phone: +41 798 340 585
Email: ggardemyr@targovax.com

Øystein Soug, CFO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com